PAREXEL International Corporation announced the establishment of a strategic functional service provider relationship with Eli Lilly and Company, a global pharmaceutical company, to support study start-up and site monitoring of clinical trials throughout the Asia/Pacific region. PAREXEL will assist Lilly in bringing greater efficiencies to its clinical research studies to help meet Lilly's development and commercialization goals.
Through the agreement, Lilly will access PAREXEL's experience in Asia and Australia for study start-up and site monitoring. The collaboration will allow Lilly to focus on its relationships with investigators and regulators and increase its flexibility, productivity and efficiency. The strategic partnership with PAREXEL enables Lilly to more effectively allocate studies and apply necessary resources to meet patient and portfolio needs.
"We are constantly evaluating how we can increase our flexibility and focus internal efforts on our core capabilities," said Jeff Kasher, Ph.D., Vice President of Global Clinical Development, Eli Lilly and Company. "This strategic agreement enables us to leverage PAREXEL's expertise in clinical trial monitoring and site start-up services throughout the Asia/Pacific region, which will increase our ability to speed innovative medicines to patients."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.